Xilio Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XLO Nasdaq 2836 xiliotx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Xilio Therapeutics, Inc.

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates - Aug 12th, 2026 5:30 am
3 Small-Cap Biotech Stocks Pairing Rapid Revenue Growth With High Insider Ownership - Jul 23rd, 2026 11:56 pm
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jul 6th, 2026 2:30 pm
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer - Jun 29th, 2026 5:30 am
Xilio Therapeutics, Inc. (XLO) Reports Q1 Loss, Beats Revenue Estimates - May 12th, 2026 6:40 am
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates - May 12th, 2026 5:30 am
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 7th, 2026 2:30 pm
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Apr 17th, 2026 2:01 pm
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors - Apr 16th, 2026 5:30 am
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? - Apr 1st, 2026 10:00 am
Cancer Stocks to Buy as Innovation Reshapes Global Oncology Market - Mar 26th, 2026 7:18 am
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results - Mar 23rd, 2026 5:30 am
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting - Mar 17th, 2026 2:45 pm
Xilio Therapeutics Announces Pricing of Underwritten Offering - Feb 11th, 2026 7:34 pm
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates - Jan 8th, 2026 6:30 am